Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully treat HCV. Unfortunately, antiviral therapy fails in some patients, resulting in a relapse of HCV.

A study published in the Journal of Clinical Investigation identifies a marker that can identify patients likely to have an HCV relapse after . Shyamasundaran Kottilil and colleagues at the NIH evaluated the immune response of HCV-infected individuals treated with . Treated patients that had increased expression of type I interferon were more likely to remain HCV-free. Patients unable to maintain a type I interferon response were more likely to have an HCV relapse.

This study provides a potential marker to identify patients prone to HCV relapse. Moreover, these results suggest that type I interferon treatment in at-risk patients merits future study.

More information: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome, J Clin Invest. DOI: 10.1172/JCI75938

Related Stories

Recommended for you

WHO shake-up approved after Ebola debacle

date 15 hours ago

The World Health Organization got the go-ahead Tuesday for a sweeping shake-up, including a $100-million war chest to battle future emergencies following the Ebola fiasco.

Soy supplements don't improve asthma

date 16 hours ago

Despite previous findings suggesting a link between soy intake and decreased asthma severity, a new study from Northwestern Medicine and the American Lung Association Asthma Clinical Research Network shows ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.